Please wait while the formulary information is being retrieved.
HAEGARDA (C1 ESTERASE INHIBITOR)
- Prevention of angioedema attack in hereditary angioedema
2,000 unit subcutaneous solution
- Inject 60 unit/kg by subcutaneous route twice weekly (every 3 or 4 days) in the abdomen rotating injection sites
3,000 unit subcutaneous solution
- Inject 60 unit/kg by subcutaneous route twice weekly (every 3 or 4 days) in the abdomen rotating injection sites
Prevention of angioedema attack in hereditary angioedema
- Inject 60 unit/kg by subcutaneous route twice weekly (every 3 or 4 days) in the abdomen rotating injection sites
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- No disease contraindications
HAEGARDA (C1 ESTERASE INHIBITOR)
- Prevention of angioedema attack in hereditary angioedema
- None
- Dizziness
- Hypersensitivity drug reaction
- Injection site sequelae
- Pharyngitis
More Frequent
Severe
Less Severe
- None
- Induration of skin
- Pain
- Pruritus of skin
- Skin rash
- Urticaria
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- Hematoma
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
C1 Esterase Inhibitor
- Severity Level:
2
- Additional Notes: Limited human data sug no known dev tox
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
C1 Esterase Inhibitor
Insufficient human data
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Prevention of angioedema attack in hereditary angioedema | |
| D84.1 | Defects in the complement system |
| 0-9 | A-Z |
|---|---|
| D84.1 | Defects in the complement system |
Formulary Reference Tool